Format

Send to

Choose Destination

Clinical Review Report: Riociguat (Adempas) [Internet].

Source

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Dec.
CADTH Common Drug Reviews.

Excerpt

The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III).

Copyright © 2015 Canadian Agency for Drugs and Technologies in Health.

Supplemental Content

Support Center